Cisplatin in Breast Cancer Treatment in BRCA1 Carriers

Hereditary Cancer in Clinical Practice - United Kingdom
doi 10.1186/1897-4287-10-s4-a17
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Hereditary Cancer in Clinical Practice
OncologyGenetics
2011English

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer

Cancers
Cancer ResearchOncology
2018English

Body Weight and Risk of Breast Cancer in BRCA1/2 Mutation Carriers

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Plasma Osteoprotegerin and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Oncotarget
Oncology
2016English

Response to Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Physical Activity and the Risk of Breast Cancer in BRCA1/2 Mutation Carriers

Breast Cancer Research and Treatment
Cancer ResearchOncology
2009English

A Prior Diagnosis of Breast Cancer Is a Risk Factor for Breast Cancer in BRCA1 and BRCA2 Carriers

Current Oncology
Oncology
2014English

Reply: Reduced DNA Repair in BRCA1 Mutation Carriers Undetectable Before Onset of Breast Cancer?

British Journal of Cancer
Cancer ResearchOncology
2007English

RASSF1A Polymorphism A133S Is Associated With Early Onset Breast Cancer in BRCA1/2 Mutation Carriers

Cancer Research
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy